The news triggered an upward rally in the stocks, with Cohance Lifesciences gaining 5.5%, Divi’s Laboratories advancing 2.5% to an intraday high of Rs 6,314.5, and SAI Life Sciences rising about 2% to Rs 943 apiece on the NSE.
According to Jefferies,India’s CRDMO (Contract Research, Development, and Manufacturing Organization) industry is experiencing a major shift, evolving from traditional chemical manufacturing to becoming a strategic partners for global innovators. This transformation is fueled by enhanced capabilities, geographic diversification, and the strategic China+1 approach, which the brokerage expects will drive a high-teen revenue CAGR over the next ten years.
Also read: Nifty bulls to regroup soon, says Anand James. Key levels to watch out for
Jefferies Top Picks and Target
SAI Life Sciences has been named Jefferies’ top pick in the sector, backed by its integrated service offerings, strong East-West presence, and high growth visibility. The firm expects a 15% revenue CAGR and 24% EBITDA CAGR over FY25–28E, with a target price of Rs 1,100, representing a 19% upside from its last close of Rs 924.
Cohance Lifesciences has been initiated with a Buy rating and a target price of Rs 1,150, implying a 28% upside from its recent close of Rs 896. Jefferies expects Cohance to post the highest growth rate among its CRDMO coverage, with EBITDA CAGR exceeding 25% over FY25–28E. The company is also viewed as the strongest ADC (Antibody-Drug Conjugate) play in the Indian listed space, supported by a strong management team and proven execution.Divi’s Laboratories has been upgraded to Buy, driven by optimism around its GLP-1 drug pipeline, with a target price of Rs 7,150, indicating a 19% upside from the closing price of Rs 6,027.Also read: Ola Electric shares rally 5% on policy talks to speed EV adoptionIndia’s CRDMO sector—a USD 3 billion revenue industry—has experienced a 14% CAGR over the past five years. However, growth has been uneven due to Covid-related demand surges followed by a slowdown. Looking ahead, Jefferies estimates a high-teen revenue CAGR of 18% between FY25 and FY30E, driven by strong pipeline visibility, Big Pharma’s diversification through the China+1 strategy, and increasing demand for weight loss and type 2 diabetes drugs (such as GLP/GIP therapies).(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
